Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana stock soars on diabetes therapy data, UniQure's offering, BioInvent's lymphoma success, Alpha's Zunveyl deal, Neumirna funding, and Cassava's layoffs.

Positive results from clinical trials often give biotechnology companies a boost, but this one was big. Shares of Sana Biotechnology —a firm with a market capitalization of less than $400 million as ...

The stock could soar even higher. Before the results were announced, the average target price among three analysts surveyed ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P.

Sana Biotechnology (SANA) and eBay (EBAY) are two of the stocks rallying this morning despite the market’s losses. Sana is ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.